Stock Symbol: OTC BB:ORMP

Diabetes is a serious chronic illness that represents a growing worldwide epidemic. According to the World Health Organization (WHO), the number of people suffering from diabetes has risen from 30 million in 1985 to almost 200 million in 2005, with projected figures suggesting that 370 million will be affected by 2030.

In the US alone, diabetes currently affects 20.8 million people. This represents 7.0 percent of the US population. Among them 35% to 45% need insulin injections to better control their diabetes.

According to analysts at Decision Resources, the total diabetes market (oral and insulin) was about US $11 billion in 2003. This market is expected to grow to US $14 billion by 2006, and the Type 2 diabetes therapeutic market is expected to exceed US $15.3 billion in 2013.

Growth of the diabetes market will be sustained through the continued expansion of the patient population due to aging, poor diet, conducting sedentary life style and excess body weight. The number of patients diagnosed is increasing due to routine screening and enhanced awareness.

Investment Considerations

	Demand for alternative insulin delivery technologies is rising
	Type 2 diabetes therapy market is expected to exceed US $15.3 billion in 2013.
	The Research team is made up of experts involved in the development of insulin capsules and also in the conversion of other polypeptides including vaccinations and other hormones into per-oral forms g. tablets.
	Effectiveness of insulin capsules is already proven successful on trials on animals at Hadassah University Hospital in Jerusalem.
	Oral insulin tablets enable the delivery of insulin in a more physiological manner than by injection.